Suppr超能文献

DNA拓扑异构酶II、遗传毒性与癌症。

DNA topoisomerase II, genotoxicity, and cancer.

作者信息

McClendon A Kathleen, Osheroff Neil

机构信息

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232-0146, USA.

出版信息

Mutat Res. 2007 Oct 1;623(1-2):83-97. doi: 10.1016/j.mrfmmm.2007.06.009. Epub 2007 Jul 3.

Abstract

Type II topoisomerases are ubiquitous enzymes that play essential roles in a number of fundamental DNA processes. They regulate DNA under- and overwinding, and resolve knots and tangles in the genetic material by passing an intact double helix through a transient double-stranded break that they generate in a separate segment of DNA. Because type II topoisomerases generate DNA strand breaks as a requisite intermediate in their catalytic cycle, they have the potential to fragment the genome every time they function. Thus, while these enzymes are essential to the survival of proliferating cells, they also have significant genotoxic effects. This latter aspect of type II topoisomerase has been exploited for the development of several classes of anticancer drugs that are widely employed for the clinical treatment of human malignancies. However, considerable evidence indicates that these enzymes also trigger specific leukemic chromosomal translocations. In light of the impact, both positive and negative, of type II topoisomerases on human cells, it is important to understand how these enzymes function and how their actions can destabilize the genome. This article discusses both aspects of human type II topoisomerases.

摘要

II型拓扑异构酶是普遍存在的酶,在许多基本的DNA过程中发挥着重要作用。它们调节DNA的欠旋和过旋,并通过使完整的双螺旋穿过它们在DNA的另一个片段中产生的瞬时双链断裂来解开遗传物质中的结和缠结。由于II型拓扑异构酶在其催化循环中产生DNA链断裂作为必要的中间体,它们每次发挥作用时都有可能使基因组片段化。因此,虽然这些酶对增殖细胞的存活至关重要,但它们也具有显著的基因毒性作用。II型拓扑异构酶的后一个方面已被用于开发几类抗癌药物,这些药物广泛用于人类恶性肿瘤的临床治疗。然而,大量证据表明这些酶也会引发特定的白血病染色体易位。鉴于II型拓扑异构酶对人类细胞的积极和消极影响,了解这些酶如何发挥作用以及它们的作用如何使基因组不稳定非常重要。本文讨论了人类II型拓扑异构酶的这两个方面。

相似文献

1
DNA topoisomerase II, genotoxicity, and cancer.
Mutat Res. 2007 Oct 1;623(1-2):83-97. doi: 10.1016/j.mrfmmm.2007.06.009. Epub 2007 Jul 3.
2
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing.
Nucleic Acids Res. 2009 Feb;37(3):738-48. doi: 10.1093/nar/gkn937. Epub 2008 Nov 28.
3
Etoposide, topoisomerase II and cancer.
Curr Med Chem Anticancer Agents. 2005 Jul;5(4):363-72. doi: 10.2174/1568011054222364.
4
Topoisomerase II Poisons: Converting Essential Enzymes into Molecular Scissors.
Biochemistry. 2021 Jun 1;60(21):1630-1641. doi: 10.1021/acs.biochem.1c00240. Epub 2021 May 19.
5
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
Prog Nucleic Acid Res Mol Biol. 2000;64:221-53. doi: 10.1016/s0079-6603(00)64006-0.
6
Topoisomerases as anticancer targets.
Biochem J. 2018 Jan 23;475(2):373-398. doi: 10.1042/BCJ20160583.
7
The use of divalent metal ions by type II topoisomerases.
Metallomics. 2010 Jul;2(7):450-9. doi: 10.1039/c003759a. Epub 2010 May 21.
8
DNA Topoisomerases.
EcoSal Plus. 2015;6(2). doi: 10.1128/ecosalplus.ESP-0010-2014.
9
Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes.
Curr Top Med Chem. 2003;3(3):321-38. doi: 10.2174/1568026033452519.
10
Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme.
Biochim Biophys Acta. 1998 Oct 1;1400(1-3):139-54. doi: 10.1016/s0167-4781(98)00132-8.

引用本文的文献

1
ICRF193 potentiates the genotoxicity of etoposide.
Sci Rep. 2025 Jun 4;15(1):19518. doi: 10.1038/s41598-025-03522-6.
2
Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications.
Curr Oncol. 2024 Dec 20;31(12):8054-8074. doi: 10.3390/curroncol31120594.
3
Modulation of AAV transduction and integration targeting by topoisomerase poisons.
Mol Ther Methods Clin Dev. 2024 Oct 28;32(4):101364. doi: 10.1016/j.omtm.2024.101364. eCollection 2024 Dec 12.
4
Recent Development of Fluoroquinolone Derivatives as Anticancer Agents.
Molecules. 2024 Jul 27;29(15):3538. doi: 10.3390/molecules29153538.
5
Understanding Cancer's Defense against Topoisomerase-Active Drugs: A Comprehensive Review.
Cancers (Basel). 2024 Feb 6;16(4):680. doi: 10.3390/cancers16040680.
8
Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents.
Pharmaceuticals (Basel). 2023 Oct 13;16(10):1456. doi: 10.3390/ph16101456.
10
Targeting mitochondrial dynamics proteins for the treatment of doxorubicin-induced cardiotoxicity.
Front Mol Biosci. 2023 Aug 3;10:1241225. doi: 10.3389/fmolb.2023.1241225. eCollection 2023.

本文引用的文献

1
Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme.
Biochemistry. 2007 Jul 17;46(28):8217-25. doi: 10.1021/bi700272u. Epub 2007 Jun 20.
2
Bioflavonoids as poisons of human topoisomerase II alpha and II beta.
Biochemistry. 2007 May 22;46(20):6097-108. doi: 10.1021/bi7000664. Epub 2007 Apr 26.
3
Cells lacking DNA topoisomerase II beta are resistant to genistein.
J Nat Prod. 2007 May;70(5):763-7. doi: 10.1021/np060609z. Epub 2007 Apr 6.
6
Topoisomerase II and the etiology of chromosomal translocations.
DNA Repair (Amst). 2006 Sep 8;5(9-10):1093-108. doi: 10.1016/j.dnarep.2006.05.031. Epub 2006 Jul 20.
7
Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations: new insights and new questions.
DNA Repair (Amst). 2006 Sep 8;5(9-10):1109-18. doi: 10.1016/j.dnarep.2006.05.018. Epub 2006 Jun 30.
8
The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy.
Mini Rev Med Chem. 2006 Apr;6(4):401-7. doi: 10.2174/138955706776361439.
10
HOX genes: seductive science, mysterious mechanisms.
Ulster Med J. 2006 Jan;75(1):23-31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验